{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:43:58Z","timestamp":1793137438724,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ctrv.2024.102791","type":"journal-article","created":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T01:34:02Z","timestamp":1719106442000},"page":"102791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"129","author":[{"given":"Arianna","family":"Marinello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7461-023X","authenticated-orcid":false,"given":"Marco","family":"Tagliamento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Pagliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Conci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Vasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo Gustavo","family":"Dall\u2019Olio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ctrv.2024.102791_b0005","first-page":"1647","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102791_b0010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102791_b0015","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102791_b0020","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102791_b0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.annonc.2023.01.008","article-title":"Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102791_b0030","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1001\/jamaoncol.2022.4457","article-title":"Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review","volume":"8","author":"Krebs","year":"2022","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102791_b0035","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: from discovery to clinical application","volume":"11","author":"Alix-Panabi\u00e8res","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102791_b0040","first-page":"67","article-title":"Soluble normal and mutated DNA sequences from single-copy genes in human blood","volume":"3","author":"Sorenson","year":"1994","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2024.102791_b0045","doi-asserted-by":"crossref","first-page":"8817","DOI":"10.1073\/pnas.1133470100","article-title":"Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations","volume":"100","author":"Dressman","year":"2003","journal-title":"PNAS"},{"issue":"45","key":"10.1016\/j.ctrv.2024.102791_b0050","doi-asserted-by":"crossref","first-page":"16368","DOI":"10.1073\/pnas.0507904102","article-title":"Detection and quantification of mutations in the plasma of patients with colorectal tumors","volume":"102","author":"Diehl","year":"2005","journal-title":"PNAS"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102791_b0055","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1073\/pnas.96.16.9236","article-title":"Digital PCR","volume":"96","author":"Vogelstein","year":"1999","journal-title":"Proc Natl Acad Sci"},{"issue":"38","key":"10.1016\/j.ctrv.2024.102791_b0060","doi-asserted-by":"crossref","first-page":"25265","DOI":"10.18632\/oncotarget.25404","article-title":"Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy","volume":"9","author":"Herbreteau","year":"2018","journal-title":"Oncotarget"},{"issue":"36","key":"10.1016\/j.ctrv.2024.102791_b0065","doi-asserted-by":"crossref","first-page":"24398","DOI":"10.18632\/oncotarget.25309","article-title":"Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer","volume":"9","author":"Takayama","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102791_b0070","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/annonc\/mdx501","article-title":"Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review","volume":"28","author":"Garc\u00eda-Foncillas","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102791_b0075","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102791_b0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2024.102791_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102595","article-title":"Strategies for improving detection of circulating tumor DNA using next generation sequencing","volume":"119","author":"T\u00e9bar-Mart\u00ednez","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2024.102791_b0090","doi-asserted-by":"crossref","unstructured":"Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403):eaan2415. doi:10.1126\/scitranslmed.aan2415.","DOI":"10.1126\/scitranslmed.aan2415"},{"key":"10.1016\/j.ctrv.2024.102791_b0095","doi-asserted-by":"crossref","unstructured":"Gale D, Lawson ARJ, Howarth K, et al. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. Galli A, ed. PLOS ONE. 2018;13(3):e0194630. doi:10.1371\/journal.pone.0194630.","DOI":"10.1371\/journal.pone.0194630"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102791_b0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0009-9120(89)80015-3","article-title":"Enzyme catalytic concentrations in human plasma after a marathon","volume":"22","author":"Soeder","year":"1989","journal-title":"Clin Biochem"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102791_b0105","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.tips.2019.01.006","article-title":"Liquid biopsies in cancer diagnosis, monitoring, and prognosis","volume":"40","author":"De Rubis","year":"2019","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102791_b0110","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.3390\/cells11121901","article-title":"Next-generation sequencing on circulating tumor DNA in advanced solid cancer: swiss army knife for the molecular tumor board? a review of the literature focused on FDA approved test","volume":"11","author":"Vasseur","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102791_b0115","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jtho.2019.11.024","article-title":"Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression","volume":"15","author":"Aldea","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102791_b0120","doi-asserted-by":"crossref","first-page":"e2200583","DOI":"10.1200\/PO.22.00583","article-title":"Liquid biopsies for circulating tumor DNA detection may reveal occult hematologic malignancies in patients with solid tumors","volume":"7","author":"Aldea","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102791_b0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic - implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102791_b0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ab.2017.11.004","article-title":"Circulating tumoral DNA: Preanalytical validation and quality control in a diagnostic laboratory","volume":"542","author":"Nikolaev","year":"2018","journal-title":"Anal Biochem"},{"key":"10.1016\/j.ctrv.2024.102791_b0135","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw3616","article-title":"Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies","volume":"372","author":"Lo","year":"2021","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102791_b0140","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41591-020-0933-1","article-title":"Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes","volume":"26","author":"Nuzzo","year":"2020","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102791_b0145","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/ng.2442","article-title":"Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues","volume":"44","author":"Landan","year":"2012","journal-title":"Nat Genet"},{"issue":"15","key":"10.1016\/j.ctrv.2024.102791_b0150","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.3390\/cancers15153959","article-title":"Methylated circulating tumor DNA in blood as a tool for diagnosing lung cancer: a systematic review and meta-analysis","volume":"15","author":"Borg","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102791_b0155","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.annonc.2023.11.008","article-title":"Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer","volume":"35","author":"Tran","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102791_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.xgen.2022.100242","article-title":"Circulating DNA fragmentomics and cancer screening","volume":"3","author":"Thierry","year":"2023","journal-title":"Cell Genomics"},{"issue":"7761","key":"10.1016\/j.ctrv.2024.102791_b0165","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102791_b0170","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1373\/clinchem.2019.308122","article-title":"Topologic analysis of plasma mitochondrial DNA reveals the coexistence of both linear and circular molecules","volume":"65","author":"Ma","year":"2019","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102791_b0175","doi-asserted-by":"crossref","first-page":"10968","DOI":"10.1038\/s41598-017-11368-w","article-title":"Molecular characterization of cell-free eccDNAs in human plasma","volume":"7","author":"Zhu","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102791_b0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102791_b0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102791_b0190","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"9111","key":"10.1016\/j.ctrv.2024.102791_b0195","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/S0140-6736(97)08229-9","article-title":"Mass screening for lung cancer with mobile spiral computed tomography scanner","volume":"351","author":"Sone","year":"1998","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102791_b0200","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1007\/s11606-020-05951-7","article-title":"Lung cancer screening with low-dose CT: a meta-analysis","volume":"35","author":"Hoffman","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102791_b0205","doi-asserted-by":"crossref","first-page":"242","DOI":"10.7326\/0003-4819-157-4-201208210-00004","article-title":"Predictive accuracy of the liverpool lung project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study","volume":"157","author":"Raji","year":"2012","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102791_b0210","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1056\/NEJMoa1211776","article-title":"Selection criteria for lung-cancer screening","volume":"368","author":"Tammem\u00e4gi","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102791_b0215","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S1470-2045(17)30597-1","article-title":"Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study","volume":"18","author":"Tammemagi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102791_b0220","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jtho.2018.11.023","article-title":"Biomarkers in lung cancer screening: achievements, promises, and challenges","volume":"14","author":"Seijo","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102791_b0225","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.csbj.2018.10.002","article-title":"Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management","volume":"16","author":"Elazezy","year":"2018","journal-title":"Comput Struct Biotechnol J"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102791_b0230","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer","volume":"377","author":"Chan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102791_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.555331","article-title":"Circulating Biomarkers for early stage non-small cell lung carcinoma detection: supplementation to low-dose computed tomography","volume":"11","author":"Kan","year":"2021","journal-title":"Front Oncol"},{"issue":"6378","key":"10.1016\/j.ctrv.2024.102791_b0240","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102791_b0245","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102791_b0250","doi-asserted-by":"crossref","unstructured":"Schrag D. A prospective study of a multi-cancer early detection blood test. Ann Oncol. 2022;33(suppl 7).","DOI":"10.1016\/j.annonc.2022.07.1029"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102791_b0255","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"7802","key":"10.1016\/j.ctrv.2024.102791_b0260","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102791_b0265","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1038\/s41467-021-24994-w","article-title":"Detection and characterization of lung cancer using cell-free DNA fragmentomes","volume":"12","author":"Mathios","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102791_b0270","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrclinonc.2013.100","article-title":"Minimal residual disease in acute myeloid leukaemia","volume":"10","author":"Hourigan","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102791_b0275","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4161\/cc.8.3.7608","article-title":"Does the cell number 10 9 still really fit one gram of tumor tissue?","volume":"8","author":"Del Monte","year":"2009","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102791_b0280","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102791_b0285","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/1874471013666191230144821","article-title":"18F-FDG PET\/CT in restaging and evaluation of response to therapy in lung cancer: state of the art","volume":"13","author":"Castello","year":"2020","journal-title":"Curr Radiopharm"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102791_b0290","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2008.02.015","article-title":"Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC)","volume":"62","author":"Decoster","year":"2008","journal-title":"Lung Cancer Amst Neth"},{"issue":"24","key":"10.1016\/j.ctrv.2024.102791_b0295","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1097\/MD.0000000000000955","article-title":"Interpretation and prognostic value of positron emission tomography-computed tomography after induction chemotherapy with or without radiation in IIIA-N2 Non-small cell lung cancer patients who receive curative surgery","volume":"94","author":"Kim","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102791_b0300","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.athoracsur.2015.09.099","article-title":"Utility of routine PET imaging to predict response and survival after induction therapy for non-small cell lung cancer","volume":"101","author":"Barnett","year":"2016","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102791_b0305","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cllc.2011.05.004","article-title":"Role of positron emission tomography in the early prediction of response to chemotherapy in patients with non\u2013small-cell lung cancer","volume":"13","author":"Skoura","year":"2012","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102791_b0310","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00259-014-2903-7","article-title":"Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis","volume":"42","author":"Im","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ctrv.2024.102791_b0315","doi-asserted-by":"crossref","unstructured":"Hwang JK, Page BJ, Flynn D, et al. Validation of the eighth edition TNM lung cancer staging system. J Thorac Oncol. 2020;15(4):649-654. doi:10.1016\/j.jtho.2019.11.030.","DOI":"10.1016\/j.jtho.2019.11.030"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102791_b0320","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB\u2013IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102791_b0325","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102791_b0330","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12916-023-02849-z","article-title":"Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis","volume":"21","author":"Zhong","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.ctrv.2024.102791_b0335","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231177008","article-title":"Prognostic value of postoperative ctDNA detection in patients with early non-small cell lung cancer: a systematic review and meta-analysis","volume":"15","author":"Guo","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102791_b0340","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102791_b0345","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102791_b0350","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1158\/2159-8290.CD-21-1486","article-title":"Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102791_b0355","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jtho.2023.05.027","article-title":"Longitudinal monitoring of circulating tumor DNA from plasma in patients with curative resected stages I to IIIA EGFR-mutant non-small cell lung cancer","volume":"18","author":"Jung","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102791_b0360","article-title":"Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small cell lung cancer","author":"Tran","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2024.102791_b0365","doi-asserted-by":"crossref","first-page":"1098128","DOI":"10.3389\/fonc.2023.1098128","article-title":"Investigate the application of postoperative ctDNA-based molecular residual disease detection in monitoring tumor recurrence in patients with non-small cell lung cancer\u2014\u2014a retrospective study of ctDNA","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102791_b0370","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non\u2013small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102791_b0375","doi-asserted-by":"crossref","unstructured":"Abbosh C, Frankell AM, Harrison T, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. Published online April 13, 2023:1-10. doi:10.1038\/s41586-023-05776-4.","DOI":"10.1038\/s41586-023-05776-4"},{"key":"10.1016\/j.ctrv.2024.102791_b0380","doi-asserted-by":"crossref","unstructured":"The TRACERx consortium, The PEACE consortium, Abbosh C, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451. doi:10.1038\/nature22364.","DOI":"10.1038\/nature22364"},{"key":"10.1016\/j.ctrv.2024.102791_b0385","doi-asserted-by":"crossref","unstructured":"The TRACERx consortium, Rosenthal R, Cadieux EL, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567(7749):479-485. doi:10.1038\/s41586-019-1032-7.","DOI":"10.1038\/s41586-019-1032-7"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102791_b0390","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1038\/s41467-021-27022-z","article-title":"Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC","volume":"12","author":"Qiu","year":"2021","journal-title":"Nat Commun"},{"issue":"21","key":"10.1016\/j.ctrv.2024.102791_b0395","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102791_b0400","doi-asserted-by":"crossref","first-page":"S1300","DOI":"10.1016\/j.annonc.2023.10.055","article-title":"LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial","volume":"34","author":"Reck","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102791_b0405","doi-asserted-by":"crossref","unstructured":"Felip E. IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC). Abstract 10 presented at: ESMO Immuno-Oncology Congress 2022; December 7, 2022; Geneva.","DOI":"10.1016\/j.iotech.2022.100106"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102791_b0410","doi-asserted-by":"crossref","first-page":"33519","DOI":"10.1038\/srep33519","article-title":"Circulating tumor DNA detection in lung cancer patients before and after surgery","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102791_b0415","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102791_b0420","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2021.01.005","volume":"153","author":"Provencio","year":"2021","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102791_b0425","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","article-title":"Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer","volume":"1","author":"Moding","year":"2020","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102791_b0430","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-022-01590-0","article-title":"The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients","volume":"21","author":"Yang","year":"2022","journal-title":"Mol Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102791_b0435","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.ccell.2023.09.007","article-title":"Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients","volume":"41","author":"Pan","year":"2023","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.ctrv.2024.102791_b0440","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102791_b0445","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jtho.2020.12.011","article-title":"Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC","volume":"16","author":"Lam","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102791_b0450","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/s41467-021-22444-1","article-title":"A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection","volume":"12","author":"Larson","year":"2021","journal-title":"Nat Commun"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T19:59:42Z","timestamp":1723665582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":90,"alternative-id":["S0305737224001191"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102791","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102791"}}